依卡倍特钠联合四联疗法治疗幽门螺杆菌阳性慢性萎缩性胃炎患者的效果  

Effects of Ecabet sodium combined with quadruple therapy in treatment of Helicobacter pylori-positive chronic atrophic gastritis

作　　者：史敬朋 SHI Jingpeng(Department of Gastroenterology of Beihai Hospital,Yantai 265701 Shandong,China)

机构地区：[1]烟台市北海医院消化内科,山东烟台265701

出　　处：《中国民康医学》2023年第19期52-54,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察依卡倍特钠联合四联疗法治疗幽门螺杆菌(Hp)阳性慢性萎缩性胃炎患者的效果。方法:选取2022年3月至2023年1月该院收治的82例Hp阳性慢性萎缩性胃炎患者进行前瞻性研究,按照随机数字表法将其分为对照组和研究组各41例。对照组采用四联疗法治疗,研究组在对照组基础上联合依卡倍特钠治疗,两组均治疗28 d,治疗后随访3个月。比较两组临床疗效、治疗后3个月Hp根除率、治疗前后炎性因子[C反应蛋白(CRP)、降钙素原(PCT)]水平和不良反应发生率。结果:研究组治疗总有效率为95.12%(39/41),高于对照组的78.05%(32/41),差异有统计学意义(P<0.05);治疗后3个月,研究组Hp根除率为97.56%(40/41),高于对照组的80.49%(33/41),差异有统计学意义(P<0.05);治疗后,两组CRP、PCT水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:依卡倍特钠联合四联疗法治疗Hp阳性慢性萎缩性胃炎患者可提高治疗总有效率和Hp根除率,降低炎性因子水平,效果优于单纯四联疗法治疗。Objective:To observe effects of Ecabet sodium combined with quadruple therapy in treatment of patients with Helicobacter pylori(Hp)-positive chronic atrophic gastritis.Methods:A prospective study was conducted on 82 patients with Hp-positive chronic atrophic gastritis admitted to this hospital from March 2022 to January 2023.They were divided into control group and study group according to the random number table method,41 cases in each.The control group was treated with quadruple therapy,while the study group was treated with Ecabet sodium on the basis of that of the control group.Both groups were treated for 28 d,and followed up for 3 months after the treatment.The clinical efficacy,the Hp eradication rate 3 months after the treatment,the levels of inflammatory factors[C-reactive protein(CRP),procalcitonin(PCT)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 95.12%(39/41),which was higher than 78.05%(32/41)in the control group,and the difference was statistically significant(P<0.05).3 months after the treatment,the eradication rate of Hp in the study group was 97.56%(40/41),which was higher than 80.49%(33/41)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CRP and PCT in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Ecabet sodium combined with quadruple therapy in the treatment of the patients with Hp-positive chronic atrophic gastritis can improve the total effective rate and the Hp eradication rate,and reduce the levels of inflammatory factors.Moreover,it is superior to single quadruple therapy.

关 键 词：依卡倍特钠 四联疗法 幽门螺杆菌 慢性萎缩性胃炎 根除率 炎性因子 不良反应 

分 类 号：R573.3[医药卫生—消化系统]